Highlight
This nonrandomized multicenter phase 2 trial demonstrates that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) yields a high objective response rate (54%) and durable responses in advanced gynecological clear cell cancers (CCCs), which traditionally have poor chemotherapy response rates. Notably, the 6-month progression-free survival was 58%, and median overall survival has not been reached, despite 35% of patients experiencing grade 3-4 immune-related adverse events. These findings suggest a substantial clinical benefit and warrant further investigation of this immunotherapy regimen in this underserved patient population.